Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients

NCT04981795 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04981795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04981795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients
Lead sponsor
Incyte Corporation
Phase
Observational
Overall status
Completed
Start date
September 20, 2021
Completion date
January 23, 2026
Enrollment
102 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma